Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 9/20 | 0.60 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.50 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.50 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.50 |
| ▸ | TDO2 | P48775 | 1/20 | 0.42 |
| ▸ | HTR3A | P46098 | 1/20 | 0.41 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.40 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.40 |
| ▸ | AR | P10275 | 1/20 | 0.38 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.38 |
| ▸ | NOS1 | P29475 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Formaldehyde SCHEMBL28252166 | 0.94 | EGFR (0.55) | EGFRPIK3CAPIK3CDFGFR4TDO2 | |
| SCHEMBL28292972 | 0.85 | PIK3CA (0.61) | EGFRPIK3CAPIK3CDFGFR4TDO2 | |
| SCHEMBL1748486 | 0.83 | EGFR (0.60) | EGFRPIK3CAPIK3CDFGFR4TDO2 | |
| SCHEMBL29894443 | 0.83 | EGFR (0.60) | EGFRPIK3CAPIK3CDFGFR4TDO2 | |
| SCHEMBL4417418 | 0.81 | EGFR (0.61) | EGFRPIK3CAPIK3CDFGFR4 | |
| SCHEMBL8644295 | 0.78 | PIK3CA (0.73) | EGFRPIK3CAPIK3CDFGFR4TDO2 | |
| SCHEMBL28292983 | 0.77 | CYP2D6 (0.47) | EGFRPIK3CAPIK3CDFGFR4 | |
| SCHEMBL4412970 | 0.77 | EGFR (0.56) | EGFRPIK3CAPIK3CDFGFR4 | |
| SCHEMBL276644 | 0.75 | EGFR (0.60) | EGFRPIK3CAPIK3CDFGFR4TDO2 | |
| SCHEMBL6380 | 0.75 | EGFR (0.60) | EGFRPIK3CAPIK3CDFGFR4TDO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119490461-A | Trifluoromethyl substituted quinazolinone compound, preparation method and application | 平顶山学院 | 2025-02-21 | — | — | CN | disclosed |
| CN-118996447-A | Phosphine-oxide substituted quinoxaline quinazolinone compound, preparation method and application thereof | 南阳师范学院 | 2024-11-22 | — | — | CN | disclosed |
| CN-108530435-B | Quinoxaline-containing 1, 4-pentadiene-3-ketone derivative, preparation method and application | 贵州大学 | 2021-08-17 | — | — | CN | disclosed |
| CN-108530427-B | Quinazoline-containing 1, 4-pentadiene-3-ketoxime ether derivative, and preparation method and application thereof | 贵州大学 | 2020-05-08 | — | — | CN | disclosed |
| CN-106928176-B | Coumarin-containing 1, 4-pentadiene-3-ketone derivative and preparation method and application thereof | 贵州大学 | 2020-02-18 | — | — | CN | disclosed |
| CN-107602493-B | A kind of 1,4- pentadiene -3- ketones derivant, the Preparation method and use of phentriazine ketone | 贵州大学 | 2019-10-25 | — | — | CN | disclosed |
| CN-107001377-B | Pyrazolo [1,5-A] pyrimidine derivatives that there is the piperidines of inhibitory activity to replace the duplication of Respiratory Syncytial Virus(RSV) (RSV) | 爱尔兰詹森科学公司 | 2019-09-10 | — | — | CN | disclosed |
| CN-106749046-B | One kind containing the 1,4- pentadiene -3- ketoxime ether derivative and preparation method thereof of 4 (3H)-quinazolinones | 贵州大学 | 2019-08-09 | — | — | CN | disclosed |
| CN-106349228-B | Substituted quianzolinones and its preparation method and application | 广东东阳光药业有限公司 | 2019-07-09 | — | — | CN | disclosed |
| CN-106749269-B | Octahydro pyrrolo- [3,4-c] azole derivatives and application thereof | 广东东阳光药业有限公司 | 2019-01-04 | — | — | CN | disclosed |
| CN-103987699-A | Quinazoline derivatives as PI3K modulators | NOVARTIS AG | 2014-08-13 | — | — | CN | disclosed |
| US-20090082349-A1 | THIAZOLONES FOR USE AS PI3 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION | 2009-03-26 | — | — | US | disclosed |
| EP-1996191-A2 | THIAZOLONES FOR USE AS PI3 KINASE INHIBITORS | SmithKline Beecham Corporation (US) | 2008-12-03 | — | — | EP | disclosed |
| US-20080261974-A1 | Novel Chemical Compounds | DUFFY KEVIN J | 2008-10-23 | — | — | US | disclosed |
| EP-1940812-A2 | NOVEL CHEMICAL COMPOUNDS | SmithKline Beecham Corporation (US) | 2008-07-09 | — | — | EP | disclosed |
| WO-2007103759-A2 | THIAZOLONES FOR USE AS PI3 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-09-13 | — | — | WO | disclosed |
| WO-2007038331-A2 | NOVEL CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-04-05 | — | — | WO | disclosed |
| US-5223622-A | QUINAZOLIN-2-ONES | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1993-06-29 | — | — | US | disclosed |
| CN-1071164-A | Nitrogen-containing heterocycle compound | EISAI CO LTD (JP) | 1993-04-21 | — | — | CN | disclosed |
| WO-1992015569-A1 | QUINAZOLINE DERIVATIVES USEFUL AS INTERMEDIATES | ZENECA LIMITED (GB) | 1992-09-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080261974-A1 | Novel Chemical Compounds | HIPK3, HIPK1, HIPK4 | EGFR 4025/4885PIK3CA 2134/4885PIK3CD 2145/4885 |
| US-20090082349-A1 | THIAZOLONES FOR USE AS PI3 KINASE INHIBITORS | PIK3CA, BTK, PI4KA | EGFR 1285/4885PIK3CA 1/4885PIK3CD 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.